PHARMACYTE BIOTECH INC
PMCBNASDAQUS Equity
$0.55▼ $0.03 (−5.94%)
Market closed · at close1h—
24h▼ 5.9%
7d▼ 8.7%
14d▼ 6.6%
30d▼ 22.3%
1y▼ 35.1%
🏦Market Cap
$312.54B
Large Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
—
Otter Score
55
Weak
Trading Snapshot
- Day Range
- $0.55 – $0.56
- 52-Week Range
- —
- Volume
- $3.75B
- Avg Volume
- $2.55B
- Shares Outstanding
- —
- Next Earnings
- Oct 10, 2026
Fundamentals Snapshot
- Annual Revenue
- $42.81B
- Last Q Revenue
- $11.26B
- P/E Ratio
- —
- P/S Ratio
- —
- EPS (TTM)
- —
- Dividend Yield
- —
Why Investors Own PMCB
- ✓High-growth profile — revenue up +51.6% YoY with expanding US Equity exposure.
- ✓Healthy economics — 79% gross margin and 16% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
Revenue (TTM)
$42.81B▲ +51.4% YoY
Gross Margin (TTM)
78.5%▲ +1.2% YoY
Operating Income (TTM)
$15.50B▲ +51.4% YoY
Free Cash Flow (TTM)
$6.64B▲ +51.4% YoY
About PHARMACYTE BIOTECH INC
A company profile for PHARMACYTE BIOTECH INC isn’t available yet — check back soon.
🦦
Otter Score Breakdown
ⓘ💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
Overall Score
Weak
55/100
Analyst Ratings
ⓘConsensus
Sell
6 analysts
Strong Buy0
Buy0
Hold3
Sell1
Strong Sell2
Ratings as of Feb 2023
Latest News & Updates
🚀
Reuters·2h ago
PHARMACYTE BIOTECH INC tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
🛰️
Barron’s·5h ago
Analysts lift PMCB price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
🌌
Barron’s·1d ago
PHARMACYTE BIOTECH INC announces new agreement to expand its footprint
The move broadens the company’s reach and could add incremental revenue over the next year.